Maynard Um
-
-
-
-
-
-
-
MIRA Pharmaceuticals sells 1.75M shares at 66% premium
-
-
-
-
-
-
-
Mira Pharma (MIRA) Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
-
-
-
-
-
-
-
MIRA's Ketamir-2 study accepted for publication in peer-reviewed journal
-
-
-
-
-
-
-
MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
-
-
-
-
-
-
-
Mira Pharma (MIRA) says Ketamir-2 has been accepted for publication in Frontiers in Pharmacology
-
-
-
-
-
-
-
MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
-
-
-
-
-
-
-
Mira Pharma (MIRA) Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

